Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic disease.

Obesity is a severe public health problem, contributing significantly to the global non-communicable disease burden, ...

The field of nutritional strategies for cardiovascular health in aging is gaining increasing attention due to the rising ...